I'd like to echo those points. I guess the question is, what are you looking at in terms of success, and what's your measurement of success? Speaking on behalf of the industry, Canada has been, in the biotechnology sector, quite successful, historically. We have almost 500 companies, 70% of which are spinouts from the early research, whether it was NRC research, university-based research, or otherwise.
The challenge for further growth is to actually see all the products that should come out. There are many on the market today, but we don't see them all because they just become part of everyday life. It is very much what we said in our recommendation. How do we get more capital to help finish the job, to really capture the value? Research in biotechnology takes eight to twelve years, from early concept to actually bringing it to market, and hundreds of millions of dollars. Angel investors are nice for getting started, but where things start to break down is where our granting councils or other areas simply can't come up with the next round of financing. Companies like our colleagues here today from Topigen, for example, will be looking for probably $30 million or $40 million in their next round of funding. That's beyond Canadian VC, especially our risk-averse venture capital market. We need access to foreign, direct investment in our companies to make sure they stay here. They're going to find that money because the technology is that good. The challenge for us is that they grow that company in Canada, in Montreal, not in San Diego.